Monocarboxylate transporter 1 (MCT1): SLC16A1 variants and associated clinical phenotypes

Abstract Background Monocarboxylate transporter 1 (MCT1), encoded by SLC16A1 , mediates the transport of monocarboxylate substrates across the plasma membrane. MCT1 deficiency was first described as a rare inherited metabolic disorder characterized by impaired lactate transport and subsequently as a disorder of ketone body trafficking, resulting in a broad clinical phenotype, while regulatory gain-of-function variants in SLC16A1 are an established cause of exercise-induced hyperinsulinemic hypoglycemia. We performed a systematic literature review to summarize the clinical, biochemical, genetic, and functional features reported in individuals with SLC16A1 variants. Results Reported individuals exhibited considerable phenotypic heterogeneity. Two major clinical presentation patterns were identified in group A ( n = 26). The first comprised exercise-induced hyperlactic acidemia with or without rhabdomyolysis, and the second was characterized by recurrent episodes of ketoacidosis, typically presenting during infancy or early childhood. Functional studies demonstrated impaired MCT1 expression or monocarboxylate transport for both groups. Group B ( n = 54) included regulatory promoter variants associated with exercise-induced hyperinsulinemic hypoglycemia. In addition, group C was composed of population studies identified several common SLC16A1 variants without associated pathology ( n = 714). Conclusions SLC16A1 variants are linked to clinical heterogeneity with manifestations that extend isolated disturbances of lactate or ketone metabolism. This review provides a comprehensive synthesis of the currently available evidence and identifies gaps that warrant further investigation to better define the pathophysiology of this inborn error of metabolism, a probably often missed diagnosis.

Authors

Institutions

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-11-14
DOI
https://doi.org/10.1186/s13023-026-04704-9
Primary Topic
Metabolism and Genetic Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Monocarboxylate transporter 1 (MCT1): SLC16A1 variants and associated clinical phenotypes

Sarah Catharina Grünert, Jörn Oliver Sass, Mariana da Silva
Orphanet Journal of Rare Diseases
Metabolism and Genetic Disorders
article

Monocarboxylate transporter 1 (MCT1): SLC16A1 variants and associated clinical phenotypes

Sarah Catharina Grünert, Jörn Oliver Sass, Mariana da Silva
article en

Abstract

Abstract Background Monocarboxylate transporter 1 (MCT1), encoded by SLC16A1 , mediates the transport of monocarboxylate substrates across the plasma membrane. MCT1 deficiency was first described as a rare inherited metabolic disorder characterized by impaired lactate transport and subsequently as a disorder of ketone body trafficking, resulting in a broad clinical phenotype, while regulatory gain-of-function variants in SLC16A1 are an established cause of exercise-induced hyperinsulinemic hypoglycemia. We performed a systematic literature review to summarize the clinical, biochemical, genetic, and functional features reported in individuals with SLC16A1 variants. Results Reported individuals exhibited considerable phenotypic heterogeneity. Two major clinical presentation patterns were identified in group A ( n = 26). The first comprised exercise-induced hyperlactic acidemia with or without rhabdomyolysis, and the second was characterized by recurrent episodes of ketoacidosis, typically presenting during infancy or early childhood. Functional studies demonstrated impaired MCT1 expression or monocarboxylate transport for both groups. Group B ( n = 54) included regulatory promoter variants associated with exercise-induced hyperinsulinemic hypoglycemia. In addition, group C was composed of population studies identified several common SLC16A1 variants without associated pathology ( n = 714). Conclusions SLC16A1 variants are linked to clinical heterogeneity with manifestations that extend isolated disturbances of lactate or ketone metabolism. This review provides a comprehensive synthesis of the currently available evidence and identifies gaps that warrant further investigation to better define the pathophysiology of this inborn error of metabolism, a probably often missed diagnosis.

Orphanet Journal of Rare Diseases
Hochschule Bonn-Rhein-Sieg (DE), University Medical Center Freiburg (DE)
Metabolism and Genetic Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon